canis - Articles
Oclacitinib
Synonym(s): Apoquel®.
Introduction
Name
- Oclacitinib (Apoquel®).
Class of drug
- Immunosuppressant.
- Agents for dermatitis, excluding corticosteroids.
- Synthetic Janus kinase (JAK) inhibitor.
Description
Chemical name
- N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl] methanesulfonamide.
Molecular formula
- C19H27N5O6S.
Molecular weight
- 453.51.
Physical properties
- Film-coated tablets containing oclacitinib maleate.
- White to off-white, oblong shaped film-coated tablets with a score-line on both sides and marked with the letters "AQ" and "S", "M" or "L" on both sides, which refer to the different strengths of tablets: "S" 3.6 mg, "M" 5.4 mg, and "L" 16 mg tablets.
- The tablets can be divided into equal halves.
Storage requirements
- Shelf life as packaged for sale: 2 years.
- Store below 25 °C.
- Any remaining half tablet should be placed back in the opened blister and stored in the original cardboard carton.
- Any remaining half tablets should be discarded after 3 days.
Uses
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Administration
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Pharmacokinetics
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Precautions
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Withdrawal Periods
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Adverse Reactions
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Further Reading
Publications
Refereed papers
- Recent references from VetMedResource and PubMed.
- Collard W T, Hummel B D, Fielder A F, King V L, Boucher J F, Mullins M A, Malpas P B, Stegemann M R (2014) The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. J Vet Pharmacol Ther 37 (3), 279-285 PubMed.
- Gonzales A J, Bowman J W, Fici G J, Zhang M, Mann D W, Mitton-Fry M (2014) Oclacitinib (APOQUEL(®) ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther 37(4), 317-324 PubMed.
- Cosgrove S B, Wren J A, Cleaver D M, Martin D D, Walsh K F, Harfst J A, Follis S L, King V L, Boucher J F, Stegemann M R (2013) Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 24(5), 479-e114 PubMed.
- Cosgrove S B, Wren J A, Cleaver D M, Walsh K F, Follis S I, King V I, Tena J K, Stegemann M R (2013) A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Vet Dermatol 24(6), pp. 587-597 PubMed.
Other sources of information
- European Medicines Agency. European Public Assessment Report. Oclacitinib. Summary of Product Characteristics.
- European Medicines Agency. European Public Assessment Report. Oclacitinib. Scientific Discussion.
- US Food and Drugs Administration. Oclacitinib. Freedom of Information Summary.
- Product web site www.apoquel.com
- Pruritus website www.itchcycle.com